Positive New Data from Phase 1/2 Trial of AT-01 Presented at 2022 American College of Cardiology Annual Scientific Session

Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced encouraging new clinical data from the University of Tennessee Graduate School of Medicine from its Phase 1/2 trial of iodine evuzamitide (124I-AT-01), the company’s pan-amyloid binding peptide in development as a radiotracer for the diagnosis of systemic amyloidosis. These data were included in poster presentations at the American College of Cardiology (ACC) Annual Scientific Session and Expo taking place April 2-4, 2022, in Washington, D.C.

The Phase 1/2 trial evaluated the ability of AT-01 to detect amyloid deposits by PET/CT imaging in patients with diverse forms of systemic amyloidosis. The trial enrolled 25 patients with AL amyloidosis, 20 with ATTR amyloidosis, 5 healthy subjects, 2 asymptomatic TTRv subjects and 5 patients with either ALECT2, AGel, ALys or AapoA1 amyloidosis.